Figure 5.
Absence of Vδ2neg γδ T cell expansion at the end of the antiviral treatment predicts recurrent CMV DNAemia/disease. At the end of antiviral treatment (49 days), data about recovery, recurrent CMV DNAemia, and recurrent disease were collected as well as the occurrence of Vδ2neg γδ T cell expansion; 94.7% (94.67% and 94.73%) of patients with recovery had a Vδ2neg γδ T cell expansion onset, and 86.1% (86% and 86.2%) of patients with recurrent CMV DNAemia and 92.6% (92.51% and 92.69%) of patients with recurrent disease were associated with the absence of Vδ2neg γδ T cell expansion.